CRNX crinetics.com Net earnings per share for the last 12 months

Public company logo of Crinetics Pharmaceuticals (CRNX)

The niche nature of orphan pathologies limits the pool of competitors, creating a foundation for a future monopoly for Crinetics Pharmaceuticals (CRNX). Net income per share over the last 12 months visualizes these expectations, where -5.09 indicates the current level of the metric. Growth prospects are bolstered by the development of paltusotine and the potential for acquisition by industry behemoths. The current lack of profitability is offset by a significant cash reserve from previous investment rounds.

CRNX (Crinetics Corp) Net earnings per share (EPS TTM) history from 07/04/2022 to 09/12/2026

Analytical breakdowns and data insights for company Crinetics Corp (CRNX)

- stock price and consensus target price:
Fundamental company valuation:Crinetics Pharmaceuticals, Inc. (CRNX)
Mass-produced product of Crinetics Pharma

For Crinetics Pharmaceuticals (CRNX), which is currently in the product cycle phase within endocrinology, the rolling annual earnings per share reflects the efficiency of innovation capitalization regardless of macroeconomic conditions. This metric is calculated by dividing the total net income over the last twelve months by the total number of outstanding shares, determining the real equity return of the business and the fundamental stability of investments in the biopharmaceutical sector.

Competitors of Crinetics Pharmaceuticals

Ascendis - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Madrigal Pharma|CORT (Corcept Therapeutics Incorporated) - Net earnings per share for the last 12 months|RYTM: Earnings per share for the last four quarters|AKRO (Akero Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Metsera Inc|Net earnings per share (EPS TTM) MLTX|Earnings per share for the last twelve months NAMS (NewAmsterdam Pharma Company)|Earnings per share for the last twelve months soleno.life SLNO|Amicus Corp (FOLD) - Net earnings per one share for the last twelve months|ETNB - Earnings per share for the last twelve months|AGIO: Earnings per share for the last twelve months|GPCR: Net earnings per share (EPS TTM)|MDXG - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Rezolute Bio|Lexicon Corp (LXRX) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months mbxbio.com (MBX)|Net earnings per share (EPS TTM) altimmune.com (ALT)|Net earnings per share (EPS TTM) AARD (aardvarktherapeutics.com)|Net earnings per share for the last four quarters Sagimet Biosciences Inc. (SGMT)|BioAge Labs, Inc - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters Biomea Fusion Corp BMEA|QNCX: Net earnings per share (EPS TTM)|Fractyl Health, Inc. (GUTS) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months VTVT|Agape ATP Corporation - Earnings per one share for the last 12 months|Net earnings per share (EPS TTM) PLUR|SYBX - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) LPCN (lipocine.com)|Net earnings per share (EPS TTM) Matinas BioPharma MTNB|SPRB: Net earnings per share for the last 12 months|Net earnings per one share for the last twelve months Galecto Corp|CTCX (Carmell Corp) - Net earnings per share for the last 12 months|Lumos Pharma Corp - Earnings per share for the trailing year|Net earnings per share for the last 12 months ONVO|Net earnings per one share for the last twelve months Radius Recycling, Inc. RDUS